Zimbabwe has declined a substantial American health deal worth 367 million US dollars (£272m) over five years because of the United States' demand for confidential data.
This move came to light following a government memo from December was disclosed, indicating that Head of State Emmerson Mnangagwa believed the deal was "unbalanced".
An official spokesperson later clarified that the US was requesting genetic material for research and commercial gain while was not willing to share the benefits from any future medical innovations.
"We will now turn to the challenging and unfortunate process of winding down our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had donated more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has called for continued talks to reach a agreement acceptable to both sides so the country's critical HIV programme can be sustained.
Wider Background
This rejection follows a similar case in neighbouring Kenya, where a high court blocked a related health funding agreement after concerns were filed about the security of Kenyans' medical information.
After resuming the presidency last year, US President Donald Trump has drastically cut foreign aid and closed the key foreign aid agency.
USAID had administered aid for the American government, but Trump argued its spending was "wasteful" and his administration was seeking government-to-government deals to enhance transparency and accountability.
Based on statements, 16 African countries have to date agreed to these new agreements, representing more than $18.3bn in new funding.
Details of the Rejected Agreement
The money for Zimbabwe would have funded "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this cooperation could have provided significant benefits for Zimbabwean communities, especially the 1.2 million presently on antiretroviral therapy through US-supported initiatives," the Ambassador said.
However, government spokesperson Nick Mangwana said the arrangement was "unfair".
"Zimbabwe was being asked to share its biological resources and data for a long time, without any equivalent assurance of access to any scientific breakthroughs – such as new medicines or tests – that could result from that shared data," he stated.
"Put simply, our country would provide the basic resources for medical research with no assurance that the end products would be accessible to our people if a new pandemic emerge."
Sovereignty and International Frameworks
He also said that the US's withdrawal from the World Health Organization (WHO) and its push of one-on-one deals were upending structures previously established via the international health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme created to manage potential global health emergencies.
"This system is designed to guarantee that when a country provides its data, the benefits – including medicines and cures – are distributed fairly, not monopolised solely by those with the capability to develop them."
These objections over the US deal "are not meant as opposition to America," he added.
"We welcome further discussions with our American counterparts on how future collaboration might be arranged in a manner that respects the independence and dignity of each country."
Medical Community Response
Medical experts expressed it recognised the official position, but urged that talks must proceed since much of the nation's Aids initiatives depended on international support.
"Where technical issues arise, including those relating to data governance or agreement terms, these can frequently be addressed via technical clarification and mutually agreed protections," it added.
The halted deal highlights the continuing debate between receiving much-needed foreign assistance and safeguarding national sovereignty in an ever more data-driven world.